Loading...
•
Sep 30
Amneal Q3 2025 Earnings Report
Amneal Pharmaceuticals reported its financial results for the third quarter ended September 30, 2025, with net revenue of $785 million and diluted income per share of $0.01.
Key Takeaways
Amneal Pharmaceuticals delivered a strong third quarter in 2025, with net revenue increasing by 12% to $785 million compared to the previous year. The company achieved a GAAP net income of $2 million and diluted income per share of $0.01. Adjusted EBITDA rose by 1% to $160 million, and adjusted diluted EPS increased by 6% to $0.17, reflecting growth across all segments and strategic product launches.
Net revenue for Q3 2025 increased by 12% to $785 million, up from $702 million in Q3 2024.
GAAP Net Income was $2 million, a significant improvement from a net loss of $0.2 million in the prior year's quarter.
Adjusted EBITDA reached $160 million, showing a 1% increase compared to Q3 2024.
Adjusted Diluted EPS grew by 6% to $0.17, compared to $0.16 in the same period last year.
Amneal
Amneal
Amneal Revenue by Segment
Revenue by Segment
Affordable Medicines Revenue
CapyFin.comSpecialty Revenue
CapyFin.comAvKARE Revenue
CapyFin.com Forward Guidance
Amneal Pharmaceuticals updated its full-year 2025 guidance, maintaining net revenue expectations while raising the lower end of adjusted EBITDA and adjusted diluted EPS ranges, and increasing operating cash flow guidance.
Positive Outlook
- Net revenue guidance maintained at $3.0 billion - $3.1 billion.
- Adjusted EBITDA guidance updated to $675 million - $685 million, raising the lower end from prior guidance.
- Adjusted diluted EPS guidance updated to $0.75 - $0.80, raising the lower end from prior guidance.
- Operating cash flow guidance increased to $300 million - $330 million.
- Operating cash flow, excluding discrete items, maintained at $300 million - $330 million.
Challenges Ahead
- No specific negative adjustments to guidance were provided in the report.
- The company cannot provide a reconciliation between non-GAAP projections and GAAP measures without unreasonable efforts due to uncertainties.
- Future results could vary materially if underlying assumptions prove inaccurate or known/unknown risks materialize.
- The guidance assumes approximately 325 million weighted-average diluted shares outstanding for the year.
- Capital expenditures are estimated at approximately $100 million, with no change from prior guidance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income